Eric Davis - BioMarin Pharmaceutical Insider

BioMarin Pharmaceutical Inc -- USA Stock  

USD 84.76  0.22  0.26%

Sr. VP, General Counsel and Secretary

Mr. G. Eric Davis serves as Executive Vice President, General Counsel and Secretary of Biomarin Pharmaceutical Inc. From December 2005 to March 2016, Mr. Davis served as our Senior Vice President, General Counsel and Secretary and from 2004 to December 2005, Mr. Davis served as our Vice President, General Counsel and Secretary. From 2000 to 2004, Mr. Davis worked in the San Francisco office of Paul Hastings LLP, where he served on the firms national securities practice committee. Mr. Davis has represented public and private companies and VC and investment banking firms in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters, and intellectual propertyrelated business transactions. His experience involves a variety of industries, including biotechnology and life sciences
Age: 45  SVP Since 2016      
Davis received a B.A. in political economy from the University of California, Berkeley, and a J.D. from the University of San Francisco School of Law.

Management Efficiency

The company has return on total asset (ROA) of (2.29) % which means that it has lost $2.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (5.73) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 1.17 B in liabilities with Debt to Equity (D/E) ratio of 41.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioMarin Pharmaceutical Inc has Current Ratio of 4.81 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company was founded in 1996 and is headquartered in San Rafael, California. BioMarin Pharmaceutical operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 2293 people.BioMarin Pharmaceutical Inc (BMRN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 2,293 people. BioMarin Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Efficient Frontier Now

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
Hide  View All  NextLaunch Efficient Frontier
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BioMarin Pharmaceutical Inc to your portfolio

Top Management

BioMarin Pharmaceutical Leadership Team
Elaine Heron, Director, MBA
Dennis Slamon, Director, Ph.D
Henry Fuchs, President, Ph.D
Robert Hombach, Director, MBA
Brian Mueller, VP
Bryan Lawlis, Director, Ph.D
JeanJacques Bienaime, Chairman, MBA
Jeff Ajer, President, MBA
Richard Meier, Director
Willard Dere, Director
Daniel Spiegelman, President, MBA
Kathryn Falberg, Director, MBA
Eric Davis, SVP
Pierre Lapalme, Chairman
Robert Baffi, EVP, MBA
Alan Lewis, Director, Ph.D
Richard Ranieri, President
David Pyott, Director, MBA
Michael Grey, Director

Stock Performance

BioMarin Pharmaceutical Performance Indicators